The effect of landiolol on cerebral blood flow in patients undergoing off-pump coronary artery bypass surgery.
OBJECTIVE
To examine the effect of landiolol on cerebral blood flow in patients with normal or deteriorated cardiac function.


METHODS
Thirty adult patients who were diagnosed with angina pectoris and who underwent elective off-pump coronary artery bypass surgery were studied. Patients were divided into two groups, one with a preoperative left ventricular ejection fraction (EF) of 50% or higher (normal EF group; n = 15) and the other with an EF of less than 50% (low EF group; n = 15). The mean cerebral blood flow velocity (Vmca) and pulsatility index (PI) in the middle cerebral artery were recorded using transcranial Doppler ultrasonography (TCD). Individual hemodynamic data were obtained using a pulmonary arterial catheter.


RESULTS
In both groups, landiolol produced a significant decrease in heart rate (HR), which then returned to baseline 15 min after administration was completed. A significant decrease in mean arterial pressure occurred in the low EF group, but the decrease was within 30% of the baseline. In the normal EF group, there was no decrease in cardiac index (CI), whereas in the low EF group, CI significantly decreased along with the decrease in HR. There were no significant differences in Vmca and PI between the two groups.


CONCLUSIONS
Continuous administration of landiolol at a dose of 0.04 mg/kg/min after 1 min rapid i.v. administration at a dose of 0.125 mg/kg/min decreases HR without causing aggravation of CBF during treatment of intraoperative tachycardia in patients with normal and deteriorated cardiac function.
Goto
Koji
K
Department of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University, Idaigaoka 1-1, Hasama, Yufu, Oita, 879-5593, Japan. ko.goto@med.oita-u.ac.jp
Hagiwara
Satoshi
S
Hidaka
Seigo
S
Yamamoto
Shunsuke
S
Kusaka
Junya
J
Yasuda
Norihisa
N
Shingu
Chihiro
C
Noguchi
Takayuki
T
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D000787:Angina Pectoris / Q000601:surgery; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D047549:Coronary Artery Bypass, Off-Pump; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D007431:Intraoperative Complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D020768:Middle Cerebral Artery / Q000000981:diagnostic imaging; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013318:Stroke Volume / Q000187:drug effects; D013610:Tachycardia / Q000188:drug therapy*; D017585:Ultrasonography, Doppler, Transcranial; D014508:Urea / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D009025:Morpholines; C077049:landiolol; D014508:Urea